Results 131 to 140 of about 136,011 (340)

Cost effectiveness of treatments for wet age-related macular degeneration [PDF]

, 2011
Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems.
Annemans, Lieven, Gallagher, Meghan, Mitchell, Paul, Thomas, Simu, White, Richard   +4 more
core   +1 more source

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Nature Communications, 2016
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits immune
Jeffrey J. Wallin, Johanna Bendell, R. Funke, M. Sznol, Konstanty Korski, Suzanne F. Jones, G. Hernandez, J. Mier, Xian He, F. Hodi, M. Denker, V. Lévêque, M. Cañamero, Galina Babitski, H. Koeppen, James Ziai, Neeraj Sharma, F. Gaire, Daniel S. Chen, D. Waterkamp, P. Hegde, David F. McDermott   +21 more
semanticscholar   +1 more source

Efficacy and tolerability of bevacizumab in patients with severe Covid-19

Nature Communications, 2020
On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesize that the anti-vascular endothelial growth factor (VEGF) drug bevacizumab might be beneficial for treating Covid-19 patients.
J. Pang, Feng Xu, G. Aondio, Y. Li, A. Fumagalli, Ming Lu, G. Valmadre, Jie Wei, Y. Bian, M. Canesi, G. Damiani, Yuan Zhang, Dexin Yu, Jun Chen, X. Ji, Wenhai Sui, Bailu Wang, Shuo Wu, A. Kovács, M. Revera, Hao Wang, Xu Jing, Ying Zhang, Yuguo Chen, Yihai Cao   +24 more
semanticscholar   +1 more source

iPRISM: Intelligent Predicting Response to Cancer Immunotherapy through Systematic Modeling

Advanced Intelligent Systems, EarlyView.
The Intelligent Predicting Response to cancer Immunotherapy through Systematic Modeling (iPRISM) model uses data from genes and immune responses to predict how well cancer patients will respond to immunotherapy. Tested on multiple cancer types, iPRISM shows higher accuracy compared to existing methods.
Yinchun Su, Siyuan Li, Qian Wang, Bingyue Pan, Jiyin Lai, Guangyou Wang, Junwei Han, Qingfei Kong   +7 more
wiley   +1 more source

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Thoracic Cancer, Volume 14, Issue 1, Page 12-23, January 2023., 2023
NSCLC patients with uncommon mutations treated with afatinib demonstrated higher survival than those given gefitinib/erlotinib. The independent predictors of progression‐free survival include dose reduction, metastases to the liver and pleura. The severity of paronychia is associated with progression‐free survival, particularly in patients with ...
John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu   +7 more
wiley   +1 more source

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. [PDF]

, 2015
BackgroundPemetrexed is approved in the treatment of advanced stage nonsquamous non-small-cell lung cancer (NSCLC). The length of response is variable, and we thus sought to identify which clinicopathologic characteristics are associated with long-term ...
Liang, Ying, Neal, Joel W, Wakelee, Heather A   +2 more
core   +1 more source

Engineering antibodies with cancer‐associated binding sites

BMEMat, EarlyView.
This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian, Yumeng Pan, Yingchun Zhang, Fangling Wang, Zejun Wang   +4 more
wiley   +1 more source

An exploration of LAF‐bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non—small cell lung cancer

Thoracic Cancer, Volume 13, Issue 23, Page 3374-3383, December 2022., 2022
Although previous studies have confirmed that low allele frequency adjusted blood‐based tumor mutational burden (LAF‐bTMB) is associated with the efficacy of immune checkpoint inhibitor (ICI) monotherapy, there has been no report on the correlation between the efficacy of LAF‐bTMB and ICI combined chemotherapy in non–small cell lung cancer (NSCLC ...
Shuyang Zhang, Lu Yang, Yaning Yang, Ying Xin, Yan Wang   +4 more
wiley   +1 more source

Bevacizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Mongolian Patients with Diabetic Macular Edema

Central Asian Journal of Medical Sciences, 2016
Objectives: To evaluate the efficacy and safety of bevacizumab monotherapy and bevacizumab therapy combined with laser therapy versus laser monotherapy in Mongolian patients with visual impairment due to diabetic macular edema (DME). Methods: One hundred
Anaraa Toishubai, Uranchimeg Davaatseren, Baasankhuu Jamyanjav, Sun Taek Lim, Bulgan Tuvaan, Munkhzaya Tsengenbayar, Munkhkhishig Batbileg, Oyunzaya Luvsantseren, Urangua Jamyansuren, Munkhsaikhan Munkhkhuyag, Unudeleg Bayaraa, Khudrenchuluun Nanjid, Yerkyebulan Muktar, Unurtsetseg Chandaga, Chimedsuren Ochir   +14 more
doaj   +1 more source

Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells [PDF]

, 2015
BACKGROUND: Circulating tumor cells (CTCs) are often undetected through the immunomagnetic epithelial cell adhesion molecule (EpCAM)-based CellSearch(®) System in breast and colorectal cancer (CRC) patients treated with bevacizumab (BEV), where low ...
GAZZANIGA, PAOLA, GRADILONE, Angela, LOTTI, Lavinia Vittoria, MASSIMI, ISABELLA, NICOLAZZO , CHIARA, PULCINELLI, FABIO MARIA, RAIMONDI, CRISTINA, Vespa, Simone   +7 more
core   +1 more source